HNGZY News and Press, Hangzhou Tigermed

2024-06-10 09:47:06 ET More on Hangzhou Tigermed Consulting Historical earnings data for Hangzhou Tigermed Consulting Financial information for Hangzhou Tigermed Consulting Read the full article on Seeking Alpha For further details see: Hangzhou Tigermed ...

Tigermed Reports Full Year 2023 Results PR Newswire HANGZHOU, China , March 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research an...

Tigermed Reports 2023 Interim Results PR Newswire HANGZHOU, China , Aug. 25, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across...

Tigermed Officially Opens International Headquarters in Hong Kong PR Newswire HONG KONG , Aug. 16, 2023 /PRNewswire/ -- Tigermed (300347.SZ/3347.HK), a leading global Contract Research Organization (CRO) providing integrated research and development solutions f...

2023-03-28 09:54:16 ET Hangzhou Tigermed Consulting press release ( OTCPK:HNGZY ): FY Revenue of RMB7.1B (+36.3% Y/Y). Net profit attributable to the owners of the Company before non-recurring gains and losses increased by 25.0% to RMB 1,539.5 million during the Reporting Peri...

Tigermed Reports Full Year 2022 Results PR Newswire HANGZHOU, China , March 28, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across...

Summary Shanghai Mabwell Biosciences out-licensed global rights (ex-China) for a rare disease drug to Disc Medicine of Cambridge, MA in a $412.5 million agreement. Aprinoia Therapeutics, a company developing products for neurodegenerative diseases, agreed to merge with SPAC Ross Acquisi...

Tigermed Completes Acquisition of Marti Farm PR Newswire HANGZHOU, China and ZAGREB, Croatia , Jan. 19, 2023 /PRNewswire/ -- Tigermed (300347.SZ/3347.HK), a leading global provider of clinical research solutions across the full lifecycle of global biopharmace...

Hangzhou Tigermed Consulting press release ( OTCPK:HNGZY ): 1H Net profit RMB876.5B Revenue of RMB3.59B (+74.8% Y/Y). Segment revenue generated from Clinical Trial Solutions reached RMB 2,172.1 million and that from Clinical-related and Lab Services reached RMB&#...

Tigermed Reports 2022 Interim Result with Strong Financial Growth PR Newswire HANGZHOU, China , Aug. 25, 2022 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider...